What caused ENTO's earnings to miss forecasts in Q3 2022?

Entero Therapeutics (ENTO) missed earnings forecasts in Q3 2022 due to a significant decline in actual revenue compared to estimates. The company's actual revenue for the quarter was $0, while the estimated revenue was $4,430. This discrepancy suggests that the company's performance fell short of market expectations, indicating a potential issue with product sales or market conditions.